Document is current
Any future updates will be listed below
-
Authors
Tatetsu, Hiro https://orcid.org/0000-0001-8131-3401
Kato, Koji
Wada, Atsushi
Hirano, Taichi
Ueno, Shikiko
Miyasato, Yuko
Yamada, Asami
Shichijo, Takafumi
Higuchi, Yusuke
Ueda, Yujiro
Nosaka, Kisato
Mikami, Yoshiki
Karube, Kennosuke
Matsuoka, Masao
Yasunaga, Jun-ichirou
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science London (24K11563)
- License Information
-
More Information
Article History
Received: 28 May 2025
Revised: 16 September 2025
Accepted: 17 September 2025
First Online: 21 October 2025
Declarations
:
: HT has received honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Ono, Nihon Shinyaku, Novartis, SymBio Pharmaceuticals Limited, Takeda Pharmaceutical, Meiji Seika Pharma, Gilead Sciences, and Abbvie Inc., and patents and royalties from Mesoblasts. Koji Kato received honoraria from Novartis, Chugai, Meiji, Gilead Sciences, Kyowa Kirin, and Bristol Myers Squibb and research funding from Chugai, Takeda, AbbVie, Novartis, Eisai, Janssen, Ono, Meiji, Daiichi Sankyo, MSD, Bristol Myers Squibb, Gilead Sciences, and Astellas. SU has received honoraria from Sobi Japan, Asahi Kasei Pharma Corporation, Alexion, Novartis Pharmaceuticals, Chugai Pharmaceutical Co., and Argenx Japan K.K. KN is an editor for the International Journal of Hematology and has received honoraria from Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Meiji Seika Pharma, Abbvie Inc., Minophagen, Dai-ichi Sankyo, and Kyowa Kirin and research funding from Kyowa Kirin and Chugai Pharmaceutical. JY has received research funding from Eisai. The rest of the authors declare no conflicts of interest.
: This study was approved by the Institutional Review Board of Kumamoto University Hospital (No. 499) and conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from the patients.
